Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 2/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | RARG | P13631 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3368868 | 0.87 | PGR (0.69) | PGRTHRBMAOBCYP2C19KDM4E | |
| SCHEMBL4421269 | 0.87 | PGR (1.00) | PGRPDK2RARARARBRARG | |
| SCHEMBL4420953 | 0.86 | PGR (0.77) | PGRTHRBPDK2RARARARB | |
| SCHEMBL4426105 | 0.85 | PGR (0.78) | PGRPDK2MAOBTP53TDP2 | |
| SCHEMBL4420948 | 0.82 | PGR (1.00) | PGRALKBH3TDP2 | |
| SCHEMBL4420638 | 0.82 | PGR (0.64) | PGRPDK2RARARARBRARG | |
| SCHEMBL4429216 | 0.82 | PGR (0.65) | PGRMAOBTDP2 | |
| SCHEMBL4419848 | 0.82 | PGR (0.64) | PGRTDP1 | |
| SCHEMBL4419225 | 0.82 | PGR (0.78) | PGRPDK2RXRATDP2 | |
| SCHEMBL4426124 | 0.81 | PGR (0.62) | PGRTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325916-A1 | 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| US-20080119537-A1 | 5-Aryl indan-1 one and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-7319152-B2 | Contraception, hormone replacement therapy, cycle-related symptoms, or benign or malignant neoplastic disease; -methyl-5-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrrole-2-carbonitrile | WYETH (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070066675-A1 | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066675-A1 | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators | PGR, CYP19A1, GNRHR | PGR 1/4885THRB 64/4885PDK2 2229/4885 |
| US-20090325916-A1 | 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS | CYP19A1, PGR, NR5A1 | PGR 2/4885THRB 86/4885PDK2 1470/4885 |
| US-20080119537-A1 | 5-Aryl indan-1 one and analogs useful as progesterone receptor modulators | CYP19A1, PGR, NR5A1 | PGR 2/4885THRB 110/4885PDK2 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.